SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Ansun Biopharma, Inc., today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.
Ansun’s CMO, Dr. Stanley Lewis, will present at Biotech Showcase™ as follows:
Date: January 9, 2019
Time: 10:45am PST
Room: Franciscan B Ballroom
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
“As we head into a Phase 3 trial of our lead compound, DAS181, we are thrilled to be part of the biotech community developing promising, novel drugs to address the unmet medical needs of the most vulnerable patients,” stated Dr. Nancy Chang, Ansun’s CEO. DAS181 is a recombinant fusion protein developed in-house by Ansun to treat patients infected with respiratory viruses that use sialic acid as the entry point for infection of their human hosts. Ansun is currently launching a Phase 3 clinical trial of DAS181 to treat hospitalized, immunocompromised patients infected with the parainfluenza virus and is planning a Phase 2 clinical trial of DAS181 to treat severely ill hospitalized patients with influenza virus. “Last year we raised $85 million in a Series A so that we could carry DAS181 forward into late stage clinical trials, and this year we intend to do that,” explained Dr. Chang.
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
“We are delighted that Ansun will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. We are thrilled to, once again, be hosting what we believe will be the great strategic networking opportunity of 2019.”
ABOUT BIOTECH SHOWCASE
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its eleventh year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.
ABOUT ANSUN BIOPHARMA, INC.
Ansun Biopharma is a clinical stage biopharmaceutical company based in San Diego, California developing first-in-class biologic therapeutics to treat the unmet medical needs of the most vulnerable patients. Ansun is currently launching a Phase 3 clinical trial of DAS181 for the treatment of PIV infection in hospitalized and immunocompromised patients. In addition to Breakthrough Therapy Designation, DAS181 has also received Fast Track designation by the U.S. FDA for this indication. Recently the company has observed activity of DAS181 against other important respiratory pathogens based on the same host-directed anti-viral mechanism. Ansun is also actively seeking to in-license or acquire other early or mid-stage biopharmaceutical compounds. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ansun-biopharma-to-present-at-biotech-showcase-2019-in-san-francisco-300773661.html
SOURCE Ansun Biopharma, Inc.